bluebird bio Toekomstige groei

Future criteriumcontroles 2/6

bluebird bio zal naar verwachting groeien in winst en omzet met respectievelijk 49% en 41.5% per jaar. De winst per aandeel zal naar verwachting groeien met 62.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -21.5% zijn.

Belangrijke informatie

49.0%

Groei van de winst

62.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	41.5%
Toekomstig rendement op eigen vermogen	-21.5%
Dekking van analisten	Good
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Recent updates

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

Nov 15

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

Jul 13

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Oct 04

Bluebird bio names interim finance chief

Sep 26

Bluebird bio jumps 17% on FDA approval of new gene therapy

Sep 19

bluebird bio' chief strategy and financial officer to depart

Sep 12

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

Aug 17

bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case

Jun 22

bluebird bio: Beaten Down Biotech With Possible Long-Term Potential

May 09

Winst- en omzetgroeiprognoses

NasdaqGS:BLUE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	311	-104	46	64	3
12/31/2025	247	-115	-179	-160	9
12/31/2024	71	-269	-315	-273	8
9/30/2024	53	-293	-271	-264	N/A
6/30/2024	55	-319	-254	-245	N/A
3/31/2024	46	-301	-248	-238	N/A
12/31/2023	29	-212	-244	-235	N/A
9/30/2023	22	-63	-209	-200	N/A
6/30/2023	9	-52	-236	-227	N/A
3/31/2023	4	-89	-276	-262	N/A
12/31/2022	4	-230	-329	-316	N/A
9/30/2022	5	-431	-447	-436	N/A
6/30/2022	6	-507	-525	-506	N/A
3/31/2022	5	-563	-574	-558	N/A
12/31/2021	4	-563	-659	-636	N/A
9/30/2021	-238	-573	-680	-651	N/A
6/30/2021	-220	-614	-678	-653	N/A
3/31/2021	-21	-480	-493	-468	N/A
12/31/2020	N/A	-561	-499	-470	N/A
9/30/2020	250	-642	-509	-474	N/A
6/30/2020	240	-653	-493	-439	N/A
3/31/2020	54	-828	-684	-616	N/A
12/31/2019	N/A	-555	-641	-564	N/A
9/30/2019	54	-715	-611	-535	N/A
6/30/2019	57	-655	-569	-496	N/A
3/31/2019	51	-605	-526	-459	N/A
12/31/2018	55	-556	-469	-413	N/A
9/30/2018	40	-524	-441	-379	N/A
6/30/2018	36	-457	N/A	-361	N/A
3/31/2018	45	-382	N/A	-314	N/A
12/31/2017	35	-336	N/A	-281	N/A
9/30/2017	33	-290	N/A	-254	N/A
6/30/2017	27	-288	N/A	-237	N/A
3/31/2017	11	-276	N/A	-228	N/A
12/31/2016	6	-264	N/A	-190	N/A
9/30/2016	6	-239	N/A	-154	N/A
6/30/2016	6	-205	N/A	-143	N/A
3/31/2016	9	-198	N/A	-111	N/A
12/31/2015	14	-167	N/A	-98	N/A
9/30/2015	19	-139	N/A	-81	N/A
6/30/2015	24	-113	N/A	-73	N/A
3/31/2015	25	-63	N/A	-72	N/A
12/31/2014	25	-49	N/A	-60	N/A
9/30/2014	25	-37	N/A	-49	N/A
6/30/2014	25	-26	N/A	-38	N/A
3/31/2014	25	-29	N/A	-35	N/A
12/31/2013	20	-25	N/A	43	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat BLUE de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat BLUE de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat BLUE de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van BLUE ( 41.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van BLUE ( 41.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat BLUE binnen 3 jaar verliesgevend zal zijn.

bluebird bio Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 24% to US$2.19

Forecast to breakeven in 2026

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

Price target decreased by 13% to US$3.67

Price target decreased by 11% to US$3.78

Price target increased by 8.0% to US$5.00

Recent updates

Price target decreased by 24% to US$2.19

bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors

New major risk - Revenue and earnings growth

Forecast to breakeven in 2026

bluebird bio, Inc. to Present Additional Long-Term Follow-Up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement under Nasdaq Listing Rule 5450(a)(1)

bluebird bio: Scientific Success And Financial Success, And The Gap Between

bluebird bio, Inc., Annual General Meeting, Nov 06, 2024

bluebird bio Announces Receipt of Expected Notices from Nasdaq Due to Non-Compliance with Nasdaq Listing Rule 5250(c)(1)

bluebird bio, Inc. Provides Revenue Guidance for the Third and Fourth Quarter of 2024

Price target decreased by 13% to US$3.67

Price target decreased by 11% to US$3.78

bluebird bio's Flight Through Financial Fog And Fierce Rivals

bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024

bluebird bio, Inc. announced delayed 10-Q filing

Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Bluebird Bio Inc

bluebird bio, Inc. announced delayed annual 10-K filing

bluebird bio Is Priced Below IP Value

Price target increased by 8.0% to US$5.00

Bluebird Bio: Innovative Therapies, Monetary Setbacks

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

New major risk - Shareholder dilution

bluebird bio, Inc. has completed a Follow-on Equity Offering in the amount of $125 million.

bluebird bio, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Consensus revenue estimates fall by 13%

Price target decreased by 8.2% to US$6.61

Bluebird Bio Inc. Presents Long-Term Data At Ash Support Beti-Ccel as A Potentially Curative Gene Therapy for -Thalassemia Patients Who Require Regular Transfusion Independence and Normal or Near- Normal- Normal- Normal-Normal Adult Hb Levels

Bluebird Bio Details Plans for the Commercial Launch of Lyfgenia(Tm) Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and A History of Vaso-Occlusive Events

Now 31% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

Bluebird Bio, Inc. to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology Annual Meeting and Exposition

Now 24% undervalued after recent price drop

bluebird bio, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?

New minor risk - Insider selling

President recently sold US$60k worth of stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation

bluebird bio, Inc. Announces FDA Priority Review of the Biologics License Application for Lovotibeglogene Autotemcel (Lovo-Cel) for Patients with Sickle Cell Disease (Scd) 12 Years and Older with a History of Vaso-Occlusive Events

Consensus revenue estimates decrease by 26%, EPS upgraded

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

bluebird bio, Inc. Appoints Joseph Vittiglio, JD as Chief Business and Legal Officer

U.S. Food and Drug Administration Lifts Partial Clinical Hold for bluebird bio, Inc.’s Sickle Cell Disease Studies for Patients Under the Age of 18

Bluebird Bio, Inc. Presents New and Updated Data At the 64Th American Society of Hematology Annual Meeting and Exposition

An unknown buyer entered into a definitive agreement to acquire SKYSONA & ZYNTEGLO of bluebird bio, Inc. (NasdaqGS:BLUE) for approximately $100 million.

Consensus forecasts updated

Less than half of directors are independent

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

bluebird bio, Inc. Appoints Christopher Krawtschuk as Treasurer, Principal Financial Officer and Principal Accounting Officer

Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo

Bluebird bio names interim finance chief

bluebird bio, Inc. Announces Executive Changes Effective October 14, 2022

Bluebird bio jumps 17% on FDA approval of new gene therapy

bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)

bluebird bio, Inc. Announces Executive Changes

bluebird bio' chief strategy and financial officer to depart

Treasurer recently sold US$78k worth of stock

Consensus forecasts updated

bluebird bio, Inc. Announces FDA Approval of Zynteglo®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions

FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia

President recently sold US$96k worth of stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target increased to US$8.22

bluebird bio, Inc. Appoints Tom Klima as Chief Commercial & Operating Officer, Effective August 8, 2022

Chief Regulatory Officer recently sold US$6.7k worth of stock